ArticleThe Journal of antimicrobial chemotherapy2026
Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesFavipiravir (T-705) shows potent in vitro activity but inconsistent in vivo efficacy. We assessed how plasma exposure and tissue distribution shape antiviral coverage using a tissue-based PK/PD framework.
methodsFavipiravir and its hydroxylated metabolite (M1) were quantified in plasma and multiple organs of Syrian golden hamsters after single and repeated dosing and compared with a non-human primate dataset. We derived tissue penetration factors (TPFs), metabolic ratios (MR) and inhibitory quotients (IQ) against published EC50 values for representative RNA viruses and integrated these results with available human pharmacokinetic data.
resultsFavipiravir absorbed rapidly and distributed heterogeneously, reaching highest levels in kidney, gut and respiratory organs with limited brain access; M1 was enriched in liver and kidney. Organ exposure ranking was broadly similar across species. Tissue IQs were often lower than plasma IQs, indicating that plasma monitoring can overestimate target-organ coverage. IQ analysis suggested favourable coverage for influenza and RSV, heterogeneous, dose-dependent coverage for chikungunya, Rift Valley fever viruses and Orthohantavirus andesense (ANDV), intermediate coverage for Zika virus, and limited coverage for SARS-CoV-2, ebolavirus and West Nile virus. For some viruses, coverage may require higher exposures, prompting dose reassessment and safety data. The IQ patterns aligned with reported preclinical efficacy, and human pharmacokinetics suggested robust exposure margins for influenza but insufficient margins for SARS-CoV-2 and ebolavirus.
conclusionsTissue-based IQs refine the interpretation of exposure-response relationships and help explain favipiravir's variable in vivo performance. The same framework can be refined and applied to other antiviral candidates to support preparedness strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.